SCHEMBL2576276

SCHEMBL2576276

COc1ccc(C(O)c2cc(OC)ccc2OCc2ccccc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.52
MAOB P27338 1/20 0.49
ALDH1A1 P00352 1/20 0.48
GAA P10253 1/20 0.48
SGMS2 Q8NHU3 1/20 0.48
ABCB1 P08183 3/20 0.48
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
MTNR1A P48039 2/20 0.46
MTNR1B P49286 2/20 0.46
HTR1A P08908 1/20 0.46
DRD2 P14416 1/20 0.46
HDAC8 Q9BY41 1/20 0.46
MAPT P10636 1/20 0.45
EGFR P00533 1/20 0.45
ERBB2 P04626 1/20 0.45
MRGPRX4 Q96LA9 1/20 0.44
C5AR1 P21730 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5266803 0.91 LMNA (0.46) LMNAMAOBALDH1A1GAASGMS2
SCHEMBL2572231 0.90 FFAR1 (0.48) LMNAMAOBALDH1A1GAASGMS2
SCHEMBL8064458 0.84 ABCB1 (0.53) LMNAALDH1A1GAASGMS2ABCB1
SCHEMBL2516365 0.83 MAPT (0.52) LMNAMAOBALDH1A1GAACYP1A2
SCHEMBL7744533 0.83 MAOB (0.51) LMNAMAOBALDH1A1GAAABCB1
SCHEMBL22498563 0.83 ADRA2A (0.51) LMNAMAOBALDH1A1GAASGMS2
SCHEMBL9188298 0.83 ADRA2A (0.51) LMNAMAOBALDH1A1GAASGMS2
SCHEMBL2580792 0.83 FFAR1 (0.48) LMNAMAOBALDH1A1GAASGMS2
SCHEMBL27774092 0.82 MAOB (0.55) LMNAMAOBALDH1A1GAASGMS2
SCHEMBL25750618 0.81 ABCB1 (0.45) LMNAMAOBALDH1A1GAASGMS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8048897-B2 Cyclohexane derivative, prodrug thereof and salt thereof, and therapeutic agent containing the same for diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-11-01 US disclosed
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2008-12-25 US disclosed
EP-1783110-A1 NOVEL CYCLOHEXANE DERIVATIVE, PRODRUG THEREOF AND SALT THEREOF, AND THERAPEUTIC AGENT CONTAINING THE SAME FOR DIABETES CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2007-05-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318874-A1 Novel Cyclohexane Derivative, Prodrug Thereof and Salt Thereof, and Therapeutic Agent Containing the Same for Diabetes SLC5A1, GPR119, SLC5A2 LMNA 3595/4885MAOB 3369/4885ALDH1A1 296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.